Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Colao, A; Ferone, D; Marzullo, P; Cappabianca, P; Cirillo, S; Boerlin, V; Lancranjan, I; Lombardi, G
   Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
   JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
   
   A. Colao et al., "Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly", J CLIN END, 86(6), 2001, pp. 2779-2786
2. Chanson, P; Boerlin, V; Ajzenberg, C; Bachelot, Y; Benito, P; Bringer, J; Caron, P; Charbonnel, B; Cortet, C; Delemer, B; Escobar-Jimenez, F; Foubert, L; Gaztambide, S; Jockenhoevel, F; Kuhn, JM; Leclere, J; Lorcy, Y; Perlemuter, L; Prestele, H; Roger, P; Rohmer, V; Santen, R; Sassolas, G; Scherbaum, WA; Schopohl, J; Torres, E; Varela, C; Villamil, F; Webb, SM
   Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
   CLINICAL ENDOCRINOLOGY
   
   P. Chanson et al., "Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly", CLIN ENDOCR, 53(5), 2000, pp. 577-586
3. Colao, A; Marzullo, P; Ferone, D; Spinelli, L; Cuocolo, A; Bonaduce, D; Salvatore, M; Boerlin, V; Lancranjan, I; Lombardi, G
   Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly
   JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
   
   A. Colao et al., "Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly", J CLIN END, 85(9), 2000, pp. 3132-3140
4. KRAENZLIN ME; SEIBEL MJ; TRECHSEL U; BOERLIN V; AZRIA M; KRAENZLIN CA; HAAS HG
   THE EFFECT OF INTRANASAL SALMON-CALCITONIN ON POSTMENOPAUSAL BONE TURNOVER AS ASSESSED BY BIOCHEMICAL MARKERS - EVIDENCE OF MAXIMAL EFFECT AFTER 8 WEEKS OF CONTINUOUS TREATMENT
   Calcified tissue international
   
   M.E. Kraenzlin et al., "THE EFFECT OF INTRANASAL SALMON-CALCITONIN ON POSTMENOPAUSAL BONE TURNOVER AS ASSESSED BY BIOCHEMICAL MARKERS - EVIDENCE OF MAXIMAL EFFECT AFTER 8 WEEKS OF CONTINUOUS TREATMENT", Calcified tissue international, 58(4), 1996, pp. 216-220
5. EZZAT S; FORSTER MJ; BERCHTOLD P; REDELMEIER DA; BOERLIN V; HARRIS AG
   CLINICAL AND BIOCHEMICAL FEATURES IN 500 PATIENTS
   Medicine
   
   S. Ezzat et al., "CLINICAL AND BIOCHEMICAL FEATURES IN 500 PATIENTS", Medicine, 73(5), 1994, pp. 233-240